Skip to main content
APVO logo

APVO · Aptevo Therapeutics Inc. · Metrics

Track APVO — free
$0.40 -0.01 (-3.36%)
Market Cap
$1.43M
Shares
3.46M
Volume · Nov 20 95.64K Avg daily vol (3M) 130.94K

APVO metrics

60 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.41
Market cap
$1.43M

Price action

23 metrics
Price change (1W)
-37.3%
Price change (30D)
-74.1%
Price change (3M)
-85.0%
Price change (6M)
-91.8%
Price change (YTD)
-95.6%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$25.02
52-week low
$0.41
Change from 52-week high
-98.3%
Change from 52-week low
+0.0%
Annualized volatility
92.4%
Annualized volatility (3M)
113.7%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.6
RSI (14D)
9.2
Price vs SMA 50
-72.1%
Price vs SMA 200
-89.3%
Avg volume (3M)
130,824
Relative volume
4.1
Average dollar volume
$198,442

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.46M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 403,249.6%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 269.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,771.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$12.50M
Operating profit (TTM)
−$25.89M
Net income (TTM)
−$25.41M
Trailing 12 months
Diluted EPS (TTM)
$1,669.05
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$369,634.31
Gross profit per diluted share (TTM)
$3,031,523.85
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$17.42

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+700.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-658.1%
Return on assets
-190.1%
Debt / equity
0.0
Current ratio
1.5
EBITDA (TTM)
−$25.70M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$8.27M
Latest balance sheet
Cash & equivalents
$8.27M
Total assets
$13.36M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$24.34M
Capital expenditures (TTM)
—
R&D (TTM)
$14.89M
SG&A (TTM)
—
Stock compensation (TTM)
$168,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
11
13F filer change QoQ
+2
Institutional ownership
9.8%
Conviction holders (share of 13F filers)
9.1%
Crowding (high-turnover and private-fund holders)
17.9%
Private-fund adviser ownership
4.9%
Active holders' share change QoQ
+294.3%
Holder tenure
1.2
Price vs estimated holder cost
-46.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.7%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1671584 CUSIP 03835L702 13F (30d) 14 filings 12 filers Visit website Investor relations